United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
UTHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for UNITED THERAPEUTICS Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 62th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 95.67%. In terms of the factors that were most noteworthy in this DCF analysis for UTHR, they are:
UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 29.7% of tickers in our DCF set.
UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 16.23. This coverage rate is greater than that of 84.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 7. This value is greater than merely 22.53% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of UNITED THERAPEUTICS Corp? See NHC, AMPH, HCSG, CBPO, and FMS.
It's my pleasure to welcome you to the United Therapeutics Corporation Second Quarter 2020 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, our Vice President of Product Development.
United Therapeutics (UTHR): Q2 Non-GAAP EPS of $3.68 beats by $0.41; GAAP EPS of $2.41 misses by $0.38.Revenue of $362M (-3.1% Y/Y) beats by $22.03M.Remodulin sales of $119M vs. consensus of $138.7M.Press Release...